Sirona Biochem to Present at the 2018 Arctic Circle Assembly

Vancouver, British Columbia – October 11, 2018 – Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the “Company”) announced today that Chief Scientific Officer, Dr. Geraldine Deliencourt-Godefroy will attend and present at the Arctic Circle Assembly. This conference will take place October 19th – 21st at the Harpa Conference Center in Reykjavik, Iceland.

The Arctic Circle Assembly is the largest international gathering on the future of the Arctic. As described by the organizers, this annual event invites attendees from 60 countries, ranging from heads of states and governments, ministers, members of parliament, officials, experts, scientists, entrepreneurs, business leaders, indigenous representatives, environmentalists, students, activists and others from the growing international community of partners and participants interested in the future of the Arctic. The Assembly covers a wide variety of topics designed in collaboration with partner organizations.

Dr. Deliencourt-Godefroy will be presenting in the Science and Traditional Knowledge Program. She’ll be discussing her work on glycoproteins based on arctic fish, a project she has been passionate about since her career began. In her post-doctoral research, Dr. Deliencourt-Godefroy was inspired by the naturally occurring antifreeze glycoproteins in the bloodstream of some fish that allow them to survive sub-zero temperatures. She has since developed a novel, patented family of compounds with a unique ability to resist stress, that are suitable for numerous commercial applications.

For over fifteen years, Dr. Deliencourt-Godefroy has continued to receive recognition for her innovative research and development within Europe, especially by the French Government. Prior to the Arctic Circle Assembly, Dr. Deliencourt-Godefroy will be attending Cosmetic 360 in Paris, France. At this global cosmetic trade fair, Sirona will be attending pre-arranged meetings as well as continuing to build networks with top industry representatives in cosmetics.

About the Arctic Circle Assembly

Established in 2013, the Arctic Circle Assembly is organized by the Arctic Circle, a non-profit organization creating a dialogue to discuss the future of the Arctic. Attended by over 2000 people from 60 countries each year, political figures, environmental experts, business leaders and scientists gather to raise global awareness of this region.

Alongside the assembly, the Arctic Circle organizes smaller forums around the world, to focus on specific environments and facilitate further discussion. For more information, visit:

About Cosmetic 360

Cosmetic 360 is an innovative-centered trade fair for the cosmetic industry. The conference brings together professionals and industry representatives from all over the world. All facets of the cosmetic industry are represented at the conference including raw materials, formulation, packaging, testing and analysis, finished products, and distribution. More information on the conference can be found at

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information regarding this press release, please contact:

Christopher Hopton, CFO
Sirona Biochem Corp.
Phone:  1.604.282.6064


Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise.  Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.